Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Document Type
- Journal article (10)
- Preprint (1)
Language
- English (11)
Keywords
- nucleotide excision repair (2)
- ChIP-sequencing (1)
- Chlamydia trachomatis (1)
- DNA damage (1)
- DNA repair (1)
- DNA-based nanostructures (1)
- DNA-processing enzymes (1)
- FANCM (1)
- LpxC inhibitors (1)
- MIZ1 (1)
- MYC (1)
- Mcl-1 (1)
- RecQ4 (1)
- Staphylococcus aureus (1)
- WDR5 (1)
- Warsaw breakage syndrome (1)
- X-ray crystallography (1)
- XPD helicase (1)
- alkene-alkyne [2+2] photocycloaddition (1)
- antibacterial activity (1)
- binding (1)
- biochemical characterization (1)
- bulky damages recognition (1)
- cancer biology (1)
- cell biology (1)
- cell-autonomous defense (1)
- deubiquitinase (1)
- enoyl-ACP reductase inhibitors (1)
- enzymes (1)
- escherichia coli (1)
- fluorescence (1)
- general transcription factor IIH (TFIIH) (1)
- genome integrity (1)
- genomic stability (1)
- helicase (1)
- human (1)
- human cells (1)
- humans (1)
- kinease (1)
- light-induced interstrand DNA crosslinking (1)
- mathematical modeling (1)
- mouse (1)
- nuclear receptors (1)
- nucleotide excision-repair (1)
- p34 (1)
- p44 (1)
- photo-cross-linking (1)
- proliferating cell nuclear antigen (PCNA) (1)
- promoter affinity (1)
- protein-DNA interaction (1)
- protein–protein interaction (1)
- recognition (1)
- repair and replication (1)
- replication fork (1)
- structural biology (1)
- substrate specificity (1)
- subunit (1)
- sulfur (1)
- transactivation (1)
- translesion synthesis (1)
- x-ray crystallography (1)
- xeroderma-pigmentosum (1)
Institute
- Rudolf-Virchow-Zentrum (11) (remove)
EU-Project number / Contract (GA) number
- 682586 (1)
Drug-target kinetics enable time-dependent changes in target engagement to be quantified as a function of drug concentration. When coupled to drug pharmacokinetics (PK), drug-target kinetics can thus be used to predict in vivo pharmacodynamics (PD). Previously we described a mechanistic PK/PD model that successfully predicted the antibacterial activity of an LpxC inhibitor in a model of Pseudomonas aeruginosa infection. In the present work we demonstrate that the same approach can be used to predict the in vivo activity of an enoyl-ACP reductase (FabI) inhibitor in a model of methicillin-resistant Staphylococcus aureus (MRSA) infection. This is significant because the LpxC inhibitors are cidal, whereas the FabI inhibitors are static. In addition P. aeruginosa is a Gram-negative organism whereas MRSA is Gram-positive. Thus this study supports the general applicability of our modeling approach across antibacterial space.